Cancer is a general term related to the abnormal (malignant) growth of cells (tumor) which tend to proliferate uncontrolled and destroy healthy tissues. If not controlled by effective treatment, cancer can spread out into other regions of the body (metastasize).
Ductal carcinoma in situ (DCIS): A form of breast carcinoma in situ confined to the breast ducts. DCIS (also called noninvasive breast cancer or intraductal breast carcinoma) is often associated with microcalcification on mammography.

Classification by the Food and Drug Administration (FDA) of medical devices according to potential risks or hazards.

(CTE) Computed tomography enterography is an imaging procedure to evaluate diseases affecting the mucosa and bowel wall of the small intestine. CTE uses oral contrast agents to improve bowel wall visualization. Several studies established that small bowel distention using negative oral contrast agent increases diagnostic performance of some abdomen CT studies.
The multi-detector row CT (MDCT) improves temporal and spatial resolution and 3D imaging processes offer a full examination of the small bowel with surrounding structures, depicting the small bowel inflammation associated with Crohn's disease by displaying mural hyperenhancement, stratification, and thickening.
CT enterography versus capsule endoscopy provides a non invasive study with comparable sensitivity, high specificity and overall accuracy.

See also Colonoscopy and Virtual Colonoscopy.

(CA) Contrast agents are used to change the imaging characteristics, resulting in additional information about anatomy, morphology or physiology of the human body. Radiocontrast agents (also called photon-based imaging agents) are used to improve the visibility of internal body structures in x-ray and CT procedures. Contrast agents are also used to increase the contrast between different tissues in MRI (magnetic resonance imaging) and ultrasound imaging. The ideal imaging agent provides enhanced contrast with little biological interaction.
First investigations with radiopaque materials are done shortly after the discovery of x-rays. These positive contrast agents attenuate x-rays more than body soft tissues due to their high atomic weight. Iodine and barium have been identified as suitable materials with high radiodensity and are used until today in x-ray and CT contrast agents. Iodine-based contrast agents are water-soluble and the solutions are used nearly anywhere in the body. Iodinated contrast materials are most administered intravenous, but can also be introduced intraarterial, intrathecal, oral, rectal, intravesical, or installed in body cavities. Barium sulfate is only used for opacification of the gastrointestinal tract. Negative contrast agents attenuate x-rays less than body soft tissues, for example gas.

Iodinated contrast media are differentiated in;

Intravascular iodinated contrast agents are required for a large number of x-ray and CT studies to enhance vessels and organs dependent on the blood supply. Injectable contrast agents are diluted in the bloodstream and rapidly distributed throughout the extracellular fluid. The main route of excretion is through the kidneys, related to the poor binding of the agent to serum albumin. The liver (gall bladder) and small intestine provide alternate routes of elimination particularly in patients with severe renal impairment. The use of special biliary contrast agents is suitable for gallbladder CT and cholecystograms because they are concentrated by the liver to be detectable in the hepatic bile.
The introduction of fast multi-detector row CT technology, has led to the development of optimized contrast injection techniques. The amount of contrast enhancement depends on the contrast agent characteristics, such as iodine concentration, osmolality, viscosity, and the injection protocol, such as iodine flux and iodine dose. Adverse reactions are rare and have decreased with the introduction of nonionic contrast agents.
See also Contrast Enhanced Computed Tomography, Abdomen CT, Contrast Media Injector, Single-Head CT Power Injector, Multi-Head Contrast Media Injector, Syringeless CT Power Injector, CT Power Injector.

Identification of an unknown radionuclide by measuring the decrease in radioactivity.

See also Decay.